UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041441
Receipt number R000047287
Scientific Title Validation study of effects of test food ingestion on subjective symptoms and performance after exercise.
Date of disclosure of the study information 2021/08/20
Last modified on 2021/07/20 18:34:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Validation study of effects of test food ingestion on subjective symptoms and performance after exercise.

Acronym

Validation study of effects of test food ingestion on subjective symptoms and performance after exercise.

Scientific Title

Validation study of effects of test food ingestion on subjective symptoms and performance after exercise.

Scientific Title:Acronym

Validation study of effects of test food ingestion on subjective symptoms and performance after exercise.

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To confirm effects for subjective symptoms and performance after exercise by 4-week consumption of test food.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Visual Analogue Scale (VAS) of muscle soreness

Key secondary outcomes

VAS of fatigue
Muscle strength
Range of motion
In the blood levels of Myoglobin, CPK, CRP, LDH, GH and Collagen
SF-8 Standard
Incidence of adverse events and of side effects


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake one package of test food dissolved in water (~100 ml) twice a day for 33 days - Wash out period [23 days] - Intake one package of control food dissolved in water (~100 ml) twice a day for 33 days

Interventions/Control_2

Intake one package of control food with water (~100 ml) twice a day for 33 days - Wash out period [23 days] - Intake one package of test food with water (~100 ml) twice a day for 33 days

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

65 years-old >

Gender

Male

Key inclusion criteria

(1) Healthy Males aged over 40 to under 65 years when informed consent was given.
(2) Those who don't currently have a habit of exercise but did in the past.
(3) Those whose BMI ranges from 18.5 kg/m2 to 30 kg/m2.
(4) Those who receive enough explanation of the test, deeply understand it, and give written consent for the participation.

Key exclusion criteria

(1) Those who have previous and/or current medical history of serious disease.
(2) Those who habitually take medicines possibly affecting the test results or who can't restrict them.
(3) Those who have allergy to medicine and/or food (including allergy to collagen and gelatin).
(4) Those who habitually take the following products possibly affecting the test results or those who can not restrict them: Food for Specified Health Uses, Food with Function Claim, Food with Nutrient Function Claim, health foods, dietary supplement, sport nutrition products (e.g., BCAA, Protein, Protein Bar, Protein Drink), energy drinks (e.g., Red Bull), and nutritional drink (e.g., Lipovitan D).
(5) Those who have a taste for collagen-rich meals such as "motsu" and "horumon", and actively take them more than 4 times a week.
(6) Those who had exercises and/or activities with muscle pain during the last one month before SCR test.
(7) Those who plan to have exercises and/or activities with muscle pain during the test period.
(8) Those who habitually have body-care.
(9) Those who can't participate in the test on schedule.
(10) Those who have smoking habit.
(11) Those who take a lot of alcohol.
(12) Those who have extremely irregular life style.
(13) Those who are currently participating in other clinical trials of medicine or health food, or who did within 4-weeks, or who plan to do just after giving informed consent.
(14) Those who donated 200 mL of whole blood and/or blood components during the last one month before starting this clinical trial.
(15) Those who donated 400 mL of whole blood during the last three months before starting this clinical trial.
(16) Those whose total blood collection volume exceeds 1200 mL when the amount of blood collection in the clinical trial and it during the last 12 months before the starting are summed.
(17) Those who have been determined ineligible to participate in this study.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Suguru
Middle name
Last name Fujiwara

Organization

CPCC Company Limited

Division name

Division of Clinical Research

Zip code

101-0047

Address

4F Sanwa-uchikanda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN

TEL

03-5297-3112

Email

cpcc-contact@cpcc.co.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Ichinohe

Organization

CPCC Company Limited

Division name

Planning & Sales Department

Zip code

101-0047

Address

4F Sanwa-uchikanda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN

TEL

03-5297-3112

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

Nippi, Incorporated

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Sanwa-Uchikanda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN

Tel

03-5297-5548

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 08 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 08 Month 05 Day

Date of IRB

2020 Year 02 Month 21 Day

Anticipated trial start date

2020 Year 08 Month 20 Day

Last follow-up date

2021 Year 01 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 08 Month 17 Day

Last modified on

2021 Year 07 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047287


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name